Page 129 - 《中国药房》2026年2期

[ 4 ] GANDHI N，DAS G M. Metabolic reprogramming in [18] PATRA K C，WANG Q，BHASKAR P T，et al. Hexoki‐
breast cancer and its therapeutic implications[J]. Cells， nase 2 is required for tumor initiation and maintenance
2019，8（2）：89. and its systemic deletion is therapeutic in mouse models
[ 5 ] NONG S Q，HAN X Y，XIANG Y，et al. Metabolic repro‐ of cancer[J]. Cancer Cell，2013，24（2）：213-228.
gramming in cancer：mechanisms and therapeutics[J]. [19] WANG G N，XU Z L，WANG C H，et al. Differential
MedComm（2020），2023，4（2）：e218. phosphofructokinase-1 isoenzyme patterns associated with
[ 6 ] WU S G，HE L，WANG Q Z，et al. An ancient Chinese glycolytic efficiency in human breast cancer and paracan‐
wisdom for metabolic engineering：Yin-Yang[J]. Microb cer tissues[J]. Oncol Lett，2013，6（6）：1701-1706.
Cell Fact，2015，14：39. [20] YANG Y M，WU K，LIU Y L，et al. Prognostic signifi‐
[ 7 ] 朱光海，王英，李元浩，等. 从“机体受邪-气机失调-浊毒 cance of metabolic enzyme pyruvate kinase M2 in breast
阻络-络网失约”浅析肿瘤病机之中医动态演变过程[J]. cancer：a meta-analysis[J]. Medicine（Baltimore），2017，96
中华中医药杂志，2020，35（8）：4097-4100. （46）：e8690.
[ 8 ] 陈舲，杨金祖，李鑫，等. 肿瘤脾虚病机与能量代谢重编 [21] VÁZQUEZ-ARREGUÍN K，MADDOX J，KANG J，et al.
程相关性探讨[J]. 中国中医药信息杂志，2025，32（3）： BRCA1 through its E3 ligase activity regulates the trans-
29-33. cription factor Oct1 and carbohydrate metabolism[J]. Mol
[ 9 ] WANG S，FU J L，HAO H F，et al. Metabolic reprogram‐ Cancer Res，2018，16（3）：439-452.
ming by traditional Chinese medicine and its role in effec‐ [22] SEMENZA G L. Hypoxia-inducible factors：coupling glu‐
tive cancer therapy[J]. Pharmacol Res，2021，170：105728. cose metabolism and redox regulation with induction of
[10] TAYYARI F，NAGANA GOWDA G A，OLOPADE O F， the breast cancer stem cell phenotype[J]. EMBO J，2017，
et al. Metabolic profiles of triple-negative and luminal A 36（3）：252-259.
breast cancer subtypes in African-American identify key [23] YANG L，HOU Y X，YUAN J，et al. Twist promotes re‐
metabolic differences[J]. Oncotarget，2018，9（14）：11677- programming of glucose metabolism in breast cancer cells
11690. through PI3K/AKT and p53 signaling pathways[J]. Onco‐
[11] TANG Z W，YE W R，CHEN H T，et al. Role of purines target，2015，6（28）：25755-25769.
in regulation of metabolic reprogramming[J]. Purinergic [24] HENSLEY C T，WASTI A T，DEBERARDINIS R J. Glu‐
Signal，2019，15（4）：423-438. tamine and cancer：cell biology，physiology，and clinical
[12] WANG D，WANG F Y，KONG X B，et al. The role of opportunities[J]. J Clin Invest，2013，123（9）：3678-3684.
metabolic reprogramming in cancer metastasis and poten‐ [25] KIM S，KIM D H，JUNG W H，et al. Expression of gluta‐
tial mechanism of traditional Chinese medicine interven‐ mine metabolism-related proteins according to molecular
tion[J]. Biomed Pharmacother，2022，153：113376. subtype of breast cancer[J]. Endocr Relat Cancer，2013，20
[13] LIBERTI M V，LOCASALE J W. The Warburg effect： （3）：339-348.
how does it benefit cancer cells?[J]. Trends Biochem Sci， [26] YANG M，VOUSDEN K H. Serine and one-carbon me‐
2016，41（3）：211-218. tabolism in cancer[J]. Nat Rev Cancer，2016，16（10）：
[14] AZAD G K，TAYLOR B P，GREEN A，et al. Prediction of 650-662.
therapy response in bone-predominant metastatic breast [27] FAN J，TENG X，LIU L，et al. Human phosphoglycerate
cancer：comparison of [ F] fluorodeoxyglucose and [ F]- dehydrogenase produces the oncometabolite D-2-hydroxy‐
18
18
fluoride PET/CT with whole-body MRI with diffusion- glutarate[J]. ACS Chem Biol，2015，10（2）：510-516.
weighted imaging[J]. Eur J Nucl Med Mol Imaging，2019， [28] CHENG C M，GENG F，CHENG X，et al. Lipid metabo‐
46（4）：821-830. lism reprogramming and its potential targets in cancer[J].
[15] LI X P，SUN J，XU Q H，et al. Oxymatrine inhibits Cancer Commun（Lond），2018，38（1）：27.
colorectal cancer metastasis via attenuating PKM2-me- [29] BALABAN S，LEE L S，VARNEY B，et al. Heterogeneity
diated aerobic glycolysis[J]. Cancer Manag Res，2020，12： of fatty acid metabolism in breast cancer cells underlies
9503-9513. differential sensitivity to palmitate-induced apoptosis[J].
[16] LEI L，HONG L L，LING Z N，et al. A potential onco‐ Mol Oncol，2018，12（9）：1623-1638.
genic role for PFKFB3 overexpression in gastric cancer [30] SCHUG Z T，PECK B，JONES D T，et al. Acetyl-CoA
progression[J]. Clin Transl Gastroenterol，2021，12（7）： synthetase 2 promotes acetate utilization and maintains
e00377. cancer cell growth under metabolic stress[J]. Cancer Cell，
[17] GARCIA S N，GUEDES R C，MATILDE MARQUES M. 2015，27（1）：57-71.
Unlocking the potential of HK2 in cancer metabolism and [31] JIN Q R，YUAN L X，BOULBES D，et al. Fatty acid syn‐
therapeutics[J]. Curr Med Chem，2019，26（41）：7285- thase phosphorylation：a novel therapeutic target in HER2-
7322. overexpressing breast cancer cells[J]. Breast Cancer Res，

中国药房 2026年第37卷第2期 China Pharmacy 2026 Vol. 37 No. 2 · 255 ·